Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Scynexis, Inc.
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
November should see FDA action on what could be the first standardized fecal microbiota transplant product, rare cancer therapies from Y-mAbs and Spectrum, uniQure/CSL’s hemophilia B gene therapy and Provention Bio’s biologic to delay type 1 diabetes.
Olorofim employs a novel mechanism of action within the antifungal space and was tested in patients with high mortality risk who had exhausted treatment options.
With sluggish sales so far for antifungal Brexafemme, approved for vulvovaginal candidiasis, Scynexis will look to out-license the product and cut staff.